Core Insights - Heartflow, Inc. reported a strong financial performance for Q4 2025, achieving a 40% year-over-year revenue growth, concluding a record year for the company [3][4][13] - The company anticipates continued growth in 2026, projecting total revenue between $218 million and $222 million, representing approximately 24% to 26% growth year-over-year [11] Financial Performance - Total revenue for Q4 2025 was $49.1 million, a 40% increase from $34.98 million in Q4 2024 [4][28] - U.S. revenue reached $44.8 million, up 41% year-over-year, while international revenue was $4.3 million, a 35% increase [4] - Gross profit for Q4 2025 was $39.1 million, compared to $26.3 million in the prior year, with a gross margin of 79.5% [5][6] - Total operating expenses were $56.8 million, or 116% of total revenue, down from 121% in the prior year [7][16] - The net loss for Q4 2025 was $24.4 million, or ($0.29) per share, significantly improved from a net loss of $33 million, or ($5.59) per share, in Q4 2024 [9][10] Annual Overview - For the full year 2025, Heartflow reported total revenue of $176 million, a 40% increase from $125.8 million in 2024 [13][28] - The gross margin for the full year was 76.8%, up from 75.1% in the previous year [15] - The net loss for 2025 was $116.8 million, or ($3.17) per share, compared to a net loss of $96.4 million, or ($17.98) per share, in 2024 [17] Market Position and Growth Strategy - Heartflow's technology is being adopted by over 1,800 institutions globally, with a focus on expanding its commercial presence [20] - The company has made significant progress in scaling account activations and driving early physician adoption of Heartflow Plaque Analysis [3] - Aetna's coverage of Heartflow Plaque Analysis has increased the total U.S. covered lives for Plaque to approximately 75% [11] Future Outlook - Heartflow's 2026 guidance reflects strong business fundamentals and confidence in consistent execution, with commercial, innovation, and clinical catalysts anticipated [3] - The company expects non-GAAP gross margin to be between 80% and 81% for 2026 [11]

Investor Presentation January 2026 Disclaimers Forward-Looking Statements This presentation includes express or implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this presentation, including statements regarding our strategy, future financial condition, future operations, projected costs, prospects, plans, objectives of management ...

Core Insights - Heartflow, Inc. announced significant findings from the FISH&CHIPS study, demonstrating that its FFRCT Analysis improves diagnostic decision-making and predicts cardiovascular events while providing substantial cost savings for healthcare systems [1][2][4] Group 1: Clinical Value - The FISH&CHIPS study, involving over 90,000 patients, is the largest FFRCT study to date, providing strong real-world evidence of the clinical benefits of Heartflow's technology [1][7] - Heartflow FFRCT Analysis predicts individual cardiovascular outcomes, including myocardial infarction (MI) and cardiovascular mortality, with lower FFRCT values correlating to higher risks of adverse events [3][5] - The technology enables clinicians to tailor care more precisely, improving patient outcomes and reducing costs [4][5] Group 2: Economic Impact - The introduction of Heartflow FFRCT Analysis into the NHS led to fewer avoidable tests and lower costs for both inpatient and outpatient care, resulting in significant savings for hospitals and patients [2][5] - The analysis indicated a per-patient cost saving of £1,042 GBP ($1,394 USD) over two years, suggesting potential annual savings of £25 million GBP ($33.45 million USD) for the health system [5] - Cost savings were observed from the first year and continued to persist in lifetime modeling, highlighting the economic viability of the technology [5] Group 3: Technological Advancements - Heartflow's platform integrates various analyses, including RoadMap™ Analysis and Plaque Analysis, enhancing the accuracy of CAD assessments [4][8] - The technology has been adopted by over 1,400 institutions globally, supported by extensive clinical validation and a large dataset of coronary imaging [8][9] - Heartflow's AI-driven solutions have been validated in over 100 studies, demonstrating high acceptance rates and reproducibility in clinical practice [8]

Core Insights - Heartflow, Inc. reported a strong third quarter for 2025, with total revenue increasing by 41% year-over-year to $46.3 million, driven by growth in its FFRCT business and an expanding installed base [3][4][9] - The company is experiencing heightened physician interest in its Heartflow Plaque Analysis, which is expected to contribute to future growth following broader commercial payor coverage [3][9] - Heartflow's gross margin improved to 76.5%, up from 75.7% in the prior year, attributed to increased revenue case volume and enhanced production efficiency [5][9] Financial Performance - Total revenue for Q3 2025 was $46.3 million, a 41% increase from $32.9 million in Q3 2024 [4][22] - U.S. revenue reached $42.5 million, reflecting a 42% year-over-year growth, while international revenue was $3.8 million, a 24% increase [4][22] - Gross profit was $35.4 million, compared to $24.9 million in the same period last year, with a gross margin of 76.5% [5][22] - Operating expenses totaled $50.5 million, representing 109% of total revenue, down from 121% in the prior year [6][22] - The net loss for Q3 2025 was $50.9 million, or ($1.04) per share, compared to a net loss of $19.1 million, or ($3.43) per share, in Q3 2024 [8][22] Operational Highlights - Heartflow launched its next-generation Heartflow Plaque Analysis with an updated algorithm and advanced visualization features [9] - The DECIDE real-world prospective registry indicated that Heartflow Plaque Analysis led to medical management changes in over half of patients beyond coronary computed tomography angiography (CCTA) alone [9] - Major payors, including UnitedHealthcare and Cigna, began coverage of Heartflow Plaque Analysis on October 1, 2025, enhancing market access [9] Future Outlook - Heartflow anticipates total revenue for the full year 2025 to be in the range of $173.0 million to $173.5 million, indicating a year-over-year growth of approximately 37.5% to 38.0% [12]